• Globe Newswire

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Globenewswire -

• Globe Newswire

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Globenewswire -

• Globe Newswire

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

• Globe Newswire

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

• Globe Newswire

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

• Globe Newswire

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe

• Globe Newswire

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars